Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Tucci

Showing results (101-110 of 154) with videos related to

Pageof 16
Sort By:
Hematological Oncology|May 20, 2017
Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana LinfomiStefano Luminari, Elda Viel, Andrés José Maria Ferreri, et al.
Haematologica|July 22, 2021
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcomeAnna Dodero, Anna Guidetti, Fabrizio Marino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2013
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana LinfomiUmberto Vitolo, Marco Ladetto, Carola Boccomini, et al.
Leukemia & Lymphoma|July 9, 2019
Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL)Flavia Salvi, Stefano Luminari, Alessandra Tucci, et al.
Haematologica|June 1, 2010
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphomaSilvia Zibellini, Daniela Capello, Francesco Forconi, et al.
Virus Evolution|June 16, 2022
Competition for dominance within replicating quasispecies during prolonged SARS-CoV-2 infection in an immunocompromised hostFrancesca Caccuri, Serena Messali, Daria Bortolotti, et al.
Leukemia & Lymphoma|March 8, 2025
A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ studyAlessandra Tucci, Alessandro Re, Chiara Pagani, et al.
Cancer|September 10, 2020
Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19Chiara Cattaneo, Rosa Daffini, Chiara Pagani, et al.
British Journal of Haematology|March 23, 2011
Integrated profiling of diffuse large B-cell lymphoma with 7q gainEkaterina Chigrinova, Michael Mian, Yulei Shen, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 8, 2018
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovirMauro Viganò, Alessandro Loglio, Sara Labanca, et al.
Pageof 16

Showing results (101-110 of 154) with videos related to

Sort By:
Pageof 16
Hematological Oncology|May 20, 2017
Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana LinfomiStefano Luminari, Elda Viel, Andrés José Maria Ferreri, et al.
Haematologica|July 22, 2021
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcomeAnna Dodero, Anna Guidetti, Fabrizio Marino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2013
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana LinfomiUmberto Vitolo, Marco Ladetto, Carola Boccomini, et al.
Leukemia & Lymphoma|July 9, 2019
Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL)Flavia Salvi, Stefano Luminari, Alessandra Tucci, et al.
Haematologica|June 1, 2010
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphomaSilvia Zibellini, Daniela Capello, Francesco Forconi, et al.
Virus Evolution|June 16, 2022
Competition for dominance within replicating quasispecies during prolonged SARS-CoV-2 infection in an immunocompromised hostFrancesca Caccuri, Serena Messali, Daria Bortolotti, et al.
Leukemia & Lymphoma|March 8, 2025
A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ studyAlessandra Tucci, Alessandro Re, Chiara Pagani, et al.
Cancer|September 10, 2020
Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19Chiara Cattaneo, Rosa Daffini, Chiara Pagani, et al.
British Journal of Haematology|March 23, 2011
Integrated profiling of diffuse large B-cell lymphoma with 7q gainEkaterina Chigrinova, Michael Mian, Yulei Shen, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 8, 2018
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovirMauro Viganò, Alessandro Loglio, Sara Labanca, et al.
Pageof 16